Report for: Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing&ndash;remitting multiple sclerosis?

Title	Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing–remitting multiple sclerosis?
Published in	Neuropsychiatric Disease and Treatment, October 2012
DOI	10.2147/ndt.s36771
Pubmed ID	23118540
Authors	Tunde Csepany, Mezei, Bereczki, Racz, Csiba
Abstract	Decreased relapse rate and slower disease progression have been reported with long-term use of immunomodulatory treatments (IMTs, interferon beta or glatiramer acetate) in relapsing-remitting multiple sclerosis. There are, however, patients who do not respond to such treatments, and they can be potential candidates for alternative therapeutic approaches.

View on publisher site Alert me about new mentions

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Geographical breakdown

Country	Count	As %
Unknown	1	100%

Demographic breakdown

Type	Count	As %
Members of the public	1	100%

Mendeley readers

The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country	Count	As %
Spain	1	6%
Unknown	16	94%

Demographic breakdown

Readers by professional status	Count	As %
Student > Ph. D. Student	5	29%
Other	2	12%
Student > Master	2	12%
Professor	2	12%
Researcher	2	12%
Other	2	12%
Unknown	2	12%

Readers by discipline	Count	As %
Medicine and Dentistry	6	35%
Psychology	2	12%
Nursing and Health Professions	1	6%
Agricultural and Biological Sciences	1	6%
Neuroscience	1	6%
Other	1	6%
Unknown	5	29%

Attention Score in Context

This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 November 2012.

All research outputs

#2,983,407

of 23,109,468 outputs

Outputs from Neuropsychiatric Disease and Treatment

#425

of 3,003 outputs

Outputs of similar age

#21,233

of 173,055 outputs

Outputs of similar age from Neuropsychiatric Disease and Treatment

of 18 outputs

Altmetric has tracked 23,109,468 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.

So far Altmetric has tracked 3,003 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.7. This one has done well, scoring higher than 85% of its peers.

Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 173,055 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.

We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.

Dove Medical Press

Article Metrics

Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing–remitting multiple sclerosis?

About this Attention Score

Mentioned by

Citations

Readers on

Twitter Demographics

Geographical breakdown

Demographic breakdown

Mendeley readers

Geographical breakdown

Demographic breakdown

Attention Score in Context